All lobbying filings

THE MCMANUS GROUP

Lobbying for FULCRUM THERAPEUTICS · Rare disease biopharma company

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · Massachusetts · House · Senate · $50,000.00 income · posted Apr 20, 2026

Official filing document

Bills named in this filing 4

HR 1796
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
S 735
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
HR 1262
Mikaela Naylon Give Kids a Chance Act
S 932
Give Kids a Chance Act of 2025

Lobbying activity 1

Health Issues

Education and advocacy regarding sickle cell disease, including H.R. 1796/S. 735- Sickle Cell Disease and Other Heritable Blood Disorders, Research, Surveillance, Prevention, and Treatment Act of 2025. Priority review vouchers: Give Kids a Chance Act of 2025 (H.R. 1262/S.932) Issues related to FDA Accelerated Approval Pathways

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.